This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

New potential drug combination for most common form of non-Hodgkin's lymphoma

November 1st, 2010

Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Although 60% of patients can be cured with a currently available combination therapy, this leaves a substantial number of patients without a cure. However, a team of researchers, led by Ari Melnick, at Weill Cornell Medical College, New York, has now identified a potential new combinatorial therapy for DLBCL. Specifically, the team found that combining an inhibitor of the protein BCL6 with either an inhibitor of HDAC proteins or an inhibitor of the Hsp90 protein enhanced killing of primary human DLBCL cells in vitro relative to the use of the BCL6 inhibitor alone. Both drug combinations also potently suppressed the growth of established human DLBCL xenografts in mice or even eradicated the tumors completely. These data provide a rational basis for designing combination therapy clinical trials in patients with DLBCL.

More information:
View this article at: www.jci.org/articles/view/4286 … 3f286442c25fdb9ce9e2

Provided by Journal of Clinical Investigation

Citation: New potential drug combination for most common form of non-Hodgkin's lymphoma (2010, November 1) retrieved 16 August 2026 from https://sciencex.com/wire-news/50070967/new-potential-drug-combination-for-most-common-form-of-non-hodgk.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.